Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Anti-PD-1 therapies are routinely used to treat many ... the combinatorial effect of simultaneously blocking the EPO signaling pathway and anti-PD-1 pathway. In those experiments, no mice with ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

BioNTech to present clinical & pre-clinical data from mRNA and next-generation immuno-oncology priority programmes at AACR 2025: Mainz, Germany Saturday, April 26, 2025, 14:00 Hrs ...

Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed a phase 3 trial in skin cancer. Novartis had hoped the COMBI-i ...